Skip to main content
SpringerLink
Log in

Adjuvanted recombinant zoster vaccine cost effective in US?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 US dollars

  2. 2016 US dollars

References

  1. Le P, et al. Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine. JAMA Internal Medicine : 9 Jul 2018. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2018.3200.

  2. Curran D, et al. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine : 13 Jul 2018. Available from: URL: http://doi.org/10.1016/j.vaccine.2018.07.005.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adjuvanted recombinant zoster vaccine cost effective in US?. PharmacoEcon Outcomes News 808, 4 (2018). https://doi.org/10.1007/s40274-018-5119-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5119-4

Search

Navigation